使用抗LAG-3示踪剂[89Zr]Zr-BI 754111的89Zr-免疫PET:在非小细胞肺癌和头颈部鳞状细胞癌中证实靶点特异性结合
本研究为一项1期试验的影像学子研究,纳入2例头颈癌和4例肺癌患者,使用抗LAG-3抗体示踪剂[89Zr]Zr-BI 754111进行PET显像,并通过增加未标记抗体质量剂量观察阻断效应以验证靶点特异性。结果显示4 mg质量剂量下肿瘤摄取清晰可见,肿瘤-血浆比值为1.63(IQR 0.37-2.89),增加质量剂量后摄取可被饱和,肿瘤摄取与免疫细胞来源RNA特征相关。作者认为该示踪剂PET显像在开发LAG-3靶向治疗的潜在预测性影像生物标志物方面显示出良好的技术和生物学特性。
要点
- 4 mg质量剂量下[89Zr]Zr-BI 754111肿瘤摄取清晰可见,肿瘤-血浆比值1.63(IQR 0.37-2.89)。
- 增加未标记抗体至44 mg或604 mg后肿瘤摄取可被饱和,证实靶点特异性结合。
- 肿瘤摄取与免疫细胞来源RNA特征相关,支持其作为预测性影像生物标志物的潜力。
核心结论
- [89Zr]Zr-BI-754111 PET显像在开发LAG-3靶向治疗的潜在预测性影像生物标志物方面显示出良好的技术和生物学特性。
研究设计与样本
- 本研究为1期试验(BI 754091联合BI 754111)的影像学子研究,纳入头颈癌2例和肺癌4例患者。
- 基线肿瘤活检及[18F]FDG-PET后给予240 mg BI 754091,8天后给予[89Zr]Zr-BI 754111(37 MBq,4 mg),注射后2 h、96 h和144 h行PET扫描。
- 为验证靶点特异性,两周后再次给药,此次预先给予40 mg(N=3)或600 mg(N=3)未标记BI 754111,注射后96 h和144 h行PET扫描。
- 肿瘤免疫细胞浸润通过免疫组化和RNA测序评估。
主要发现
- 4 mg质量剂量下肿瘤摄取清晰可见,肿瘤-血浆比值为1.63(IQR 0.37-2.89)。
- 增加质量剂量后肿瘤摄取可被饱和:44 mg组为0.67(IQR 0.50-0.85),604 mg组为0.56(IQR 0.42-0.75),证实靶点特异性。
- 肿瘤摄取与免疫细胞来源RNA特征相关。
关键数值与推荐
- [89Zr]Zr-BI 754111给药活度为37 MBq、质量剂量4 mg。
- 靶点特异性验证中未标记BI 754111预给剂量为40 mg(N=3)或600 mg(N=3)。
- PET扫描时间点为注射后2 h、96 h和144 h。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [89Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. METHODS: Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [18F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration of [89Zr]Zr-BI 754111 (37 MBq, 4 mg). PET scans were performed 2 h, 96 h, and 144 h post-injection. To investigate target specificity, a second tracer administration was given two weeks later, this time with pre-administration of 40 (N = 3) or 600 mg (N = 3) unlabeled BI 754111, followed by PET scans at 96 h and 144 h post-injection. Tumor immune cell infiltration was assessed by immunohistochemistry and RNA sequencing. RESULTS: Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50-0.85]; 604 mg: 0.56 [IQR 0.42-0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. CONCLUSIONS: [89Zr]Zr-BI-754111 PET imaging shows favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03780725. Registered 19 December 2018.
引用
- Miedema IHC, Huisman MC, Zwezerijnen GJC, et al. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. Eur J Nucl Med Mol Imaging. 2023. PMID: 36859619. doi:10.1007/s00259-023-06164-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。